Graham Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Graham Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,532	Closed	-$280K	–	1172
2025 Q4	$280K	Sell	1,532 -1,075	-41%	-$150K	0.01%	888
2025 Q3	$317K	Sell	2,607 -1,777	-41%	-$200K	0.01%	838
2025 Q2	$458K	Buy	+4,384	New	+$464K	0.01%	862
2024 Q2	–	Sell	-9,553	Closed	-$762K	–	1043
2024 Q1	$762K	Buy	+9,553	New	+$802K	0.01%	496
2023 Q4	–	Sell	-13,255	Closed	-$926K	–	1004
2023 Q3	$926K	Buy	+13,255	New	+$991K	0.02%	390
2022 Q2	–	Sell	-101,851	Closed	-$4.21M	–	1003
2022 Q1	$4.21M	Buy	101,851 +78,518	+337%	+$2.43M	0.15%	68
2021 Q4	$881K	Buy	+23,333	New	+$859K	0.04%	106

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Graham Capital Management's AXSM Position: Q1 2026 in Review

Graham Capital Management sold out of Axsome Therapeutics (AXSM) in Q1 2026, closing a stake of 1,532 shares — an estimated $280K sold.

Graham Capital Management first reported a position in AXSM in Q4 2021 and held it in 7 quarters. The position peaked at $4.21M in Q1 2022. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

Graham Capital Management reported no remaining Axsome Therapeutics position as of Q1 2026 after selling out during the quarter.
Graham Capital Management sold 1,532 Axsome Therapeutics shares in Q1 2026, an estimated $280K.
Graham Capital Management first reported a position in Axsome Therapeutics in Q4 2021 and held it in 7 quarters.
Graham Capital Management's Axsome Therapeutics position peaked at $4.21M in Q1 2022.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Graham Capital Management's 13F filing for Q1 2026, filed 15 May 2026.